

Prevalence of Microalbuminuria in Diabetic Patients in Al-Najaf City

Dr. Safaa A. Khudhair, F.I.C.M.S

Iraq / Najaf / Kufa University / College of Medicine

Abstract

Background: Diabetic nephropathy accounts for a significant reduction in life expectancy of diabetic patients, approximately 80% of Type 1 diabetic patients and 30% of type 2 diabetic patients with microalbuminuria progress to overt nephropathy after 10–15 years.

Objective: To determine the prevalence of micro- and macro-albuminuria in diabetic patients in AL-Najaf city and the predictive value of some risk factors.

Method: Urinary albumin-creatinine ratio (ACR) in a spot early morning urine sample was used and the patients were categorized as normo-albuminuric when $ACR < 30$ mg/g, micro-albuminuric when $30 < ACR < 300$ and macro-albuminuric when $ACR \geq 300$ mg/g.

Results: Prevalence of albuminuria among Type 1 patients was 4(67%) microalbuminuria, 0% macroalbuminuria, i.e. 67% had abnormal urinary albumin-creatinine ratio (ACR). The corresponding prevalence for Type 2 patients was 26(52%) micro-albuminuria, 4(8%) macro-albuminuria and total of 30(60%) for abnormal urinary albumin-creatinine ratio (ACR).

Conclusion: The occurrence of microalbuminuria detected in this study was much higher than previously reported in other studies and the duration of diabetes was the strongest predictor.

Key words: diabetes mellitus, microalbuminuria, diabetic nephropathy.

Introduction

Diabetic nephropathy accounts for a significant reduction in life expectancy of diabetic patients. It is the leading cause of end-stage renal disease in the developed countries, as well as the developing countries^(1,2).

Extensive studies in the Western world have demonstrated that diabetic patients with microalbuminuria have increased risk of progression to overt proteinuria, and after some time, renal failure. The progression of diabetic nephropathy from the appearance of clinical proteinuria to end stage renal failure is usually irreversible. Without any intervention, approximately 80% of Type 1 patients with persistent microalbuminuria develop overt nephropathy after 10–15 years. Eventually 50% of these develop end stage

renal failure within 10 years and 75% by 20 years⁽³⁾.

In Type 2 diabetic patients, 20–40% with microalbuminuria progress to overt nephropathy after 20 years from onset of diabetes⁽⁴⁾, approximately 20% develop end stage renal failure⁽⁵⁾. There is a racial difference in the prevalence of diabetic nephropathy and end stage renal failure.

Early medical treatment and lifestyle adjustments have been shown to halt the progression from micro- to macroalbuminuria and eventually end stage renal failure^(6,7). Therefore, detection of microalbuminuria as early as possible in the course of the disease is very important. In the developing countries, this is even more so because of the economical constraints, kidney replacement therapy is seldom an option.

Aim of the study

The aim of this study was to determine the prevalence of microalbuminuria and diabetic nephropathy among Type 1 and Type 2 Iraqi diabetic patients in AL-Najaf city. We also planned to assess the interrelation of microalbuminuria with basic patient socio-demographic features as well as clinical and biochemical parameters.

Patients and Methods

Patients attending the outpatient clinic in Al-Hakim center for diabetic researches for their regular visits and who accept to participate in the study were included. The study was done from February to October 2007. Informed consent verbally was obtained from all patients and they were interviewed using a standardized questionnaire. The history included age, sex, duration of diabetes since diagnosis, and past history for previously diagnosed hypertension. Patients were classified into Type 1 and Type 2 according to the WHO clinical stage criteria⁽⁸⁾ according to information from each patient's file that is already present in the centre and data collected at enrolment.

Assessment of the control of diabetes

Because of lack of the laboratory facility to measure the glycosylated hemoglobin, the control of blood sugar in the individual patient was assessed by reviewing the serial fasting serum glucose measurement during the last six months, we considered patients with average fasting serum glucose exceeds or equal to 150 mg/dl to have a poor control, while those with average serum glucose less than 150 mg/dl were considered

to have an accepted control for the purpose of this study.

Clinical assessment

Weight was measured without shoes or heavy clothing. Height was determined to the nearest 0.5 cm. Blood pressure was measured with a suitable mercury sphygmomanometer After a 10 minutes rest with the patient in the sitting position. We defined the "hypertensive" patient as that who has a history of previously diagnosed and treated elevated blood pressure in addition to those with negative history and have a SBP ≥ 140 and/or DBP of ≥ 90 mmHg⁽⁹⁾.

The presence of sensory neuropathy was tested in every patient by examining the vibration sensation (using a standard tuning fork of 128 hertz frequency on the tip of the big toe, the first metatarsophalangeal joint, the medial malleolus, tibial tuberosity) and the pain sensation (by the perception of pinprick testing five points on the sole of the foot in addition to the rest of the lower limbs). Patient who has an abnormal or absent sensation on two or more areas in either test was considered to have a peripheral neuropathy, with the exclusion of those who have a known neurological defect⁽¹⁰⁾.

Assessment of urinary albumin excretion

A morning sample was collected for each patient and tested within 1 hour of collection. Urine albumin and creatinine concentrations were measured by spectrophotometry method using standard reagents of BIOLABO France Company. Urine albumin/creatinine ratio (ACR) was calculated for each patient and then the

patients were categorized as those with normal urinary albumin excretion (ACR of < 30 mg/g), microalbuminuria (30–300 mg/g) and macroalbuminuria (≥ 300 mg/g)⁽⁴⁾. Patients with fever, urinary tract infection, heart failure, and menstruation were excluded as these conditions may give false positive results of albuminuria⁽¹¹⁾.

Statistical analysis

Differences between proportions were assessed by Chi-square test. P value <0.05 was considered statistically significant.

Results

Socio-demographic characteristics of the study population

Sixty seven patients were consecutively enrolled, 11 were excluded because of concomitant conditions like heart failure, menstruation, urinary tract infection, and fever. Among the remaining patients 30(53.6%) were females and 26(46.4%) males, 6 patients (10.7%) were classified as Type 1 while the other 50 (89.3%) as Type 2. Type 1 patients were younger than Type 2 patients (median age 24.5 vs 54.3 years) and had shorter known duration with diabetes (6.5 vs 10.8 years) [table1].

Table 1. patient criteria

Type of DM	Total No. of patients	Mean age (years) M \pm SD	Mean duration of DM in years M \pm SD	Percentage of albuminuric patients
I	6	24.5 \pm 10.97	6.5 \pm 1.97	66.67%
II	50	54.3 \pm 7.72	10.8 \pm 6.94	60%
Total	56	51.61 \pm 12.4	10.23 \pm 6.71	60.71%

Albuminuria

The overall prevalence of albuminuria in diabetic patients was 60.71%. Prevalence among Type1 patients was 4(67%) microalbuminuria, 0% macroalbuminuria, i.e. 67% had abnormal urinary albumin-creatinine ratio (ACR). The corresponding

prevalence for Type 2 patients was 26(52%) micro-albuminuria, 4(8%) macro-albuminuria and total of 30(60%) for abnormal urinary albumin-creatinine ratio (ACR). [Table 2]

TABLE 2. Relation between micro- and macroalbuminuria and of risk factors

variable		normal	proteinuria			P value
			Micro-albuminuria	Macro-albuminuria	Total proteinuria	
Type of DM	type 1	2 (33 %)	4 (67 %)	0 (0%)	4 (67 %)	0.06
	type2	20 (40%)	26 (52%)	4 (8%)	30 (60%)	
Duration	<5 yrs	6 (67 %)	3 (33 %)	0(0 %)	3 (33 %)	0.02
	>5 yrs	16 (34 %)	27 (58 %)	4 (8 %)	31 (66%)	
control	good	3(75%)	1(25%)	0(0 %)	1(25%)	0.03
	poor	19(37%)	29(55 %)	4(8 %)	33(63 %)	
neuropathy	absent	15(50 %)	14(47 %)	1(3 %)	15(50 %)	0.02
	present	7(27 %)	16(62 %)	3(11 %)	19(73 %)	
BP	normal	18(47 %)	19(50 %)	1(3 %)	20(53 %)	0.04
	hypertension	4(22 %)	11(61 %)	3(17 %)	14(78 %)	
age	<40 yrs	4(57 %)	3(43 %)	0(0 %)	3(43 %)	0.04
	>40 yrs	18(37 %)	27(55 %)	4(8 %)	31(63 %)	
sex	male	10(38 %)	14(54 %)	2(8 %)	16(62 %)	0.10
	female	12(40 %)	16(53 %)	2(7 %)	18(60 %)	
BMI	<25	8(40 %)	11(55 %)	1(5 %)	12(60 %)	0.10
	>25	14(39 %)	19(53 %)	3(8 %)	22(61 %)	

Albuminuria and the associated risk factors

There was significant correlation of the prevalence of proteinuria in diabetic patients with duration of diabetes, control of

blood glucose, presence of neuropathy, hypertension, and age. But there was no significant correlation of proteinuria with sex and body mass index. [Table 2 , 3]

Table 3. The difference in duration of diabetes between the normal and the high ACR groups in diabetes type I and type II

Type of diabetes	Mean duration \pm SD	
	Normal ACR	Albuminuria
Type I	6 \pm 1.4	9.25 \pm 2.36
Type II	7.75 \pm 5.98	12.63 \pm 6.94

Discussion

This cross sectional study reveals the prevalence of microalbuminuria and its determinants in a selected population from the diabetic clinic in Al-Hakim centre in AL-Najaf city, Iraq

In this study, the prevalence for albuminuria among type 1 diabetic patients who had median diabetes duration of 6 years was 66.67% which is higher than prevalence found by other similar studies among Caucasian and African type 1 diabetic

patients, Other studies in Caucasians have reported prevalence of microalbuminuria in Type 1 patients from 7–22% and in Africans from 12-53%⁽¹²⁾.

Among the Type 2 patients in our study albuminuria was 60%, this is also higher than findings in Caucasian (8–32%) and African (10-57%) Type 2 patients^(12,13,15-18).

Differences in methods for collection of urine and assessment of microalbuminuria, and patient populations may contribute to the differences found between the results of this study and the others. Some studies have

shown decay in albumin concentration when urine samples were stored [19-21], unlike this study in which the samples was not stored for more than one hour. The way of assessing albuminuria in this study should not have caused lower prevalence of microalbuminuria.

The great percentage of the patients with poorly controlled blood glucose in our target group (95%) may contribute to the higher prevalence of albuminuria in this study. Racial difference may have a role. Decreasing prevalence of microalbuminuria and micro-vascular complications have been reported from western countries, which is attributed to improvement in metabolic control, better treatment of hypertension, the use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers^(22,23).

Among Type 2 Caucasian patients (unlike Africans), the association of diabetes duration and microalbuminuria was equivocal^(24,25). In the current study, patients with abnormal ACR had longer known diabetes duration than those with normal ACR (9.25 versus 6 years), for Type 1 and (12.63 versus 7.75 years, $p < 0.05$) for Type 2.

Poor glycaemic control is well defined contributor to the development and progression of microalbuminuria among Type 2 patients⁽²⁴⁻²⁷⁾, as well as Type 1 patients^(28,29). Hypertension is documented as the most significant contributing factor in the pathogenesis and the progression of abnormal albumin excretion rate and eventually development of diabetic nephropathy in both Type 1 and Type 2 diabetic patients⁽³⁰⁻³²⁾.

In this study the patients with poor glycaemic control and hypertension have significantly higher prevalence of micro- & macro-albuminuria as compared with the well-controlled and the normotensive groups respectively (P value < 0.05).

Conclusion

1. The occurrence of microalbuminuria detected in this study is much higher than previously reported in other studies performed in other countries.
2. The duration of diabetes was the strongest predictor; peripheral neuropathy, control of blood sugar, and hypertension as well predict increased albumin excretion rate.

References

1. Raine AE: Epidemiology, development and treatment of endstage renal failure in type 2 (non-insulin-dependent) diabetic patients in Europe. *Diabetologia* 1993, 36:1099-1104.
2. Ritz E: Nephropathy in type 2 diabetes. *J Intern Med* 1999, 245:111-126.
3. Orchard TJ, *et al.*: Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. *Diabetes* 1990, 39:1116-1124.
4. Nicolas A. Boon, Nicki R. Colledge, Brian R. Walker: Chapter 21, Davidson's principles and practice of medicine. 20th edition, Pp 841,842
5. Parving HH, *et al.*: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. *Kidney Int* 1992, 41:758-762.
6. Hasslacher C, *et al.*: Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients. *Diabetologia* 1993, 36:1051-1056.
7. Mogensen CE: Microalbuminuria as a predictor of clinical diabetic nephropathy. *Kidney Int* 1987, 31:673-689.
8. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998, 15:539-553.
9. WHO: International Society of Hypertension guidelines for the management of hypertension. *J Hypertens* 1999,17:151-183.
10. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. Lower extremity disease procedures manual. January 2001
11. Nicolas A. Boon, Nicki R. Colledge, Brian R. Walker: Chapter 17, Davidson's principles and practice of medicine. 20th edition, P 478

12. Cederholm J, *et al.*: Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. *Diabetes Res Clin Pract* 2005, 67:258-266.
13. Marshall SM, Alberti KG: Comparison of the prevalence and associated features of abnormal albumin excretion in insulin- dependent and non-insulin-dependent diabetes. *Q J Med* 1989, 70:61-71.
14. Mathiesen ER, *et al.*: Prevalence of microalbuminuria in children with type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 1986, 29:640-643.
15. Janet Joy, *et al.*: Microalbuminuria among Type 1 and Type 2 diabetic patients of African origin in Dar Es Salaam, Tanzania. [.biomedcentral/1471-2369/8/2](http://biomedcentral/1471-2369/8/2)
16. Bruno G, *et al.*: Prevalence and risk factors for microand macroalbuminuria in an Italian population-based cohort of NIDDM subjects. *Diabetes Care* 1996, 19:43-47.
17. Gatling W, Mullee MA, Hill RD: The prevalence of proteinuria detected by Albustix in a defined diabetic population. *Diabet Med* 1988, 5:256-260.
18. Gall MA, *et al.*: Prevalence of microand macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulindependent) diabetic patients. *Diabetologia* 1991, 34:655-661.
19. Collins AC, *et al.*: Storage temperature and differing methods of sample preparation in the measurement of urinary albumin. *Diabetologia* 1993, 36:993-997.
20. Osberg I, *et al.*: Effects of storage time and temperature on measurement of small concentrations of albumin in urine. *Clin Chem* 1990, 36:1428-1430.
21. Hara F, *et al.*: Studies of diabetic nephropathy. I. Effects of storage time and temperature on microalbuminuria. *Biol Pharm Bull* 1994, 17:1241-1245
22. Hovind P, *et al.*: Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. *Diabetes Care* 2003, 26:1258-1264.
23. Mohsin F, *et al.*: Discordant trends in microvascular complications in adolescents with type 1 diabetes from 1990 to 2002. *Diabetes Care* 2005, 28:1974-1980.
24. Schmitz A, Vaeth M: Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. *Diabet Med* 1988, 5:126-134.
25. Gall MA, *et al.*: Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. *Bmj* 1997, 314:783-788.
26. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *Bmj* 1998, 317:703-713.
27. Phillips CA, Molitch ME: The relationship between glucose control and the development and progression of diabetic nephropathy. *Curr Diab Rep* 2002, 2:523-529.
28. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. *Kidney Int* 1995, 47:1703-1720.
29. Wiseman M, *et al.*: Glycaemia, arterial pressure and micro-albuminuria in type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 1984, 26:401-405.
30. Mogensen CE: Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. *J Intern Med* 2003, 254:45-66.
31. Schmitz A, Vaeth M, Mogensen CE: Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. *Diabetologia* 1994, 37:1251-1258.
32. UK Prospective Diabetes Study (UKPDS). X. Urinary albumin excretion over 3 years in diet-treated type 2, (non-insulin- dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia. *Diabetologia* 1993, 36:1021-1029.